Pre-discharge installation of SGLT2 inhibitors showed a positive trend (44.2 vs 20% in HF(m)rEF patients and 29.4 vs 4% in HFpEF, both p = 0.01) HF-event-free survival at 90 days numerically favored the intervention group (29.9 vs 44.3%, p = 0.054), whereas length of hospital stay increased by 1 day (p = 0.011).<h4>Conclusion</h4>Implementing a local updated AHF protocol improved adoption of several evidence based AHF interventions. The gene discussed is SLC5A2; the disease is hydrops fetalis.